HIV-1 Strain and Primary Drug Resistance in Canada

Surveillance Report to June 30, 2001

Previous | Table of Contents | Next

Information to the readers of HIV-1 Strain and Primary Drug Resistance in Canada

The Division of HIV/AIDS Epidemiology and Surveillance and the National HIV Laboratories at the Centre for Infectious Disease Prevention and Control, Health Canada, are pleased to provide you with HIV-1 Strain and Primary Drug Resistance in Canada: Surveillance Report to June 30, 2001. Primary drug resistance is a term used to identify resistance observed in HIV-infected individuals who have never before received treatment and so presumably have been infected with a drug-resistant strain of HIV.

This report presents data that are shared by provinces participating in the Canadian HIV Strain and Drug Resistance Surveillance Program. The Division of HIV/AIDS Epidemiology and Surveillance is responsible for data management, data analysis, writing and coordination of the publication of this report. The Division of Retrovirus Surveillance is responsible for coordinating the collection of the HIV data. The National Laboratory for HIV Genetics is responsible for conducting the strain and primary drug resistance genotyping.

The major finding in this surveillance report is that primary drug resistance to anti-retroviral drugs (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors) has been identified in 5.9% of our sample population of 481 treatment naïve individuals. Resistance to more than one class of anti-retroviral drug has been identified in 0.2% of the sample population. With respect to HIV-1 subtypes, subtype B continues to predominate in Canada with 91.6% of the samples subtyped (n=919) belonging to this group, but HIV-1 subtypes A, C, D, E (also called recombinant A/E), recombinant A/C, and recombinant A/G have been identified across Canada. There is geographic variation in the prevalence of non-B HIV-1 subtypes, and this variation is likely related to travel and migration from countries where other subtypes predominate.

From a public health perspective, primary drug resistance may not yet be a significant problem in Canada, but it will no doubt play a significant role in shaping the course of the HIV epidemic in Canada and worldwide. For this reason, the data from the Canadian HIV Strain and Drug Resistance Surveillance Program will be valuable in guiding Canada's response to the public health problems posed by drug-resistant HIV, including our efforts to develop treatment strategies and effective prevention programs. The introduction of variant HIV-1 subtypes into Canada also requires vigilant monitoring in order to ensure that diagnostic and screening algorithms can adequately detect all circulating strains and to inform vaccine research and development.

This is the first report of results from the Canadian HIV Strain and Drug Resistance Surveillance Program. We will be working towards improving this report to reflect changes in the surveillance of HIV strain and drug resistance. We welcome and appreciate your comments and suggestions.

Yours sincerely,

Previous | Table of Contents | Next